Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-19-0966
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Author Correction: HER Kinase Inhibition in Patients With HER2- And HER3-mutant Cancers

Nature
Multidisciplinary
2019English

Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer

Clinical Cancer Research
Cancer ResearchOncology
2016English

HER2-Orientated Therapy in Early and Metastatic Breast Cancer

Breast Care
SurgeryOncology
2016English

HER2 Expression in NF1 Breast Cancer—Response

Cancer Prevention Research
MedicineCancer ResearchOncology
2019English

Retrospective Analysis of HER2 Therapy Interruption in Patients Responding to the Treatment in Metastatic HER2+ Breast Cancer

ESMO Open
Cancer ResearchOncology
2017English

Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer

Clinical Cancer Research
Cancer ResearchOncology
2019English

Inhibition of Ezrin Causes PKCα-mediated Internalization of Erbb2/Her2 Tyrosine Kinase in Breast Cancer Cells

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2018English

Assessing the Tolerability and Efficacy of First-Line Chemotherapy in Elderly Patients With Metastatic HER2−ve Breast Cancer

ecancermedicalscience
Cancer ResearchOncology
2019English

PTEN Expression as a Predictor for the Response to Trastuzumab-Based Therapy in Her-2 Overexpressing Metastatic Breast Cancer

PLoS ONE
Multidisciplinary
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy